Tokyo Medical University Hachioji Medical Center

Hachiōji, Tokyo 1930998

3 studies enrolling now · 12 studies all time

What they study most

Asthma, COVID-19, COVID-19 Infection, Diabetic Macular Edema (DME), Macular Degeneration, Macular Edema Secondary to Retinal Vein Occlusion, Moderate to Severe Chronic Obstructive Pulmonary Disease, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD), Psoriasis

Studies at this site

• A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised — Recruiting now
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease — Recruiting now
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma — Recruiting now
• A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) — Completed
• Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration — Running, not enrolling
• Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema — Running, not enrolling
• Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye — Completed
• EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 — Completed
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) — Stopped early
• A Study of Baricitinib (LY3009104) in Participants With COVID-19 — Completed
• A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration — Completed